Department of Orthopaedic Surgery, Affiliated Hospital, Hainan Medical College, #33 Longhua Road, Haikou, Hainan Province, People's Republic of China.
Biomed Mater. 2013 Dec;8(6):065007. doi: 10.1088/1748-6041/8/6/065007. Epub 2013 Nov 28.
A partially converted, biodegradable coralline hydroxyapatite/calcium carbonate (CHACC) composite comprising a coral calcium carbonate scaffold enveloped by a thin layer of hydroxyapatite was used in the present study. The CHACC was characterized using powder x-ray diffraction, scanning electron microscopy and energy dispersive x-ray spectroscopy. The ability of the CHACC to promote conductive osteogenesis was assessed in vitro using human mesenchymal stem cells (hMSCs) and in vivo using an immunodeficient mouse model. The clinical performance of CHACC as a bone substitute to fill voids caused by excision of bone tumours was also observed in 16 patients. The CHACC was found to consist of two overlapping layers both morphologically and chemically. Hydroxyapatite formed a thin layer of nanocrystals on the surface and a thick rough crystal layer of around 30 µm in thickness enveloping the rock-like core calcium carbonate exoskeletal architecture. hMSCs cultured on CHACC in osteogenic medium demonstrated significant osteogenic differentiation. After subcutaneous implantation of CHACC incorporating osteogenically differentiated hMSCs and an anti-resorptive agent, risedronate, into an immunodeficient mouse model, bone formation was observed on the surface of the implants. Clinical application of CHACC alone in 16 patients for bone augmentation after tumour removal showed that after implantation, visible callus formation was observed at one month and clinical bone healing achieved at four months. The majority of the implanted CHACC was degraded in 18-24 months. In conclusion, CHACC appears to be an excellent biodegradable bone graft material. It biointegrates with the host, is osteoconductive, biodegradable and can be an attractive alternative to autogenous grafts.
一种部分转化的、可生物降解的珊瑚羟磷灰石/碳酸钙（CHACC）复合材料，由珊瑚碳酸钙支架包裹一层薄的羟磷灰石组成，在本研究中被使用。CHACC 通过粉末 X 射线衍射、扫描电子显微镜和能量色散 X 射线光谱进行了表征。使用人骨髓间充质干细胞（hMSCs）在体外评估了 CHACC 促进导电性成骨的能力，并用免疫缺陷小鼠模型进行了体内评估。还在 16 名患者中观察了 CHACC 作为骨替代物填充因切除骨肿瘤而产生的空洞的临床性能。结果发现 CHACC 在形态和化学上都由两个重叠的层组成。羟磷灰石在表面形成一层纳米晶的薄层，在厚约 30µm 的粗糙晶体层中包裹着类似岩石的核心碳酸钙外骨骼结构。在成骨培养基中培养的 hMSCs 在 CHACC 上表现出明显的成骨分化。将成骨分化的 hMSCs 和抗吸收剂利塞膦酸钠（risedronate）掺入免疫缺陷小鼠模型中，然后将 CHACC 皮下植入后，观察到植入物表面有骨形成。在 16 名患者中，单独使用 CHACC 进行肿瘤切除后的骨增强的临床应用表明，植入后一个月可见骨痂形成，四个月时临床骨愈合。大多数植入的 CHACC 在 18-24 个月内降解。总之，CHACC 似乎是一种优秀的可生物降解骨移植材料。它与宿主生物整合，具有骨诱导性、可生物降解性，是自体移植物的一种有吸引力的替代品。
